The director of solid tumor therapy at Stanford Medicine describes how cellular therapies are transforming cancer care.

Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease ...

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have been given an average rating of “Moderate Buy” by the thirteen research firms that are currently covering the firm, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Peptides have emerged as versatile tools in various scientific fields, with their structural complexity and biological ...

Immunotherapy has transformed the field of cancer medicine. It has extended survival rates, reduced toxicity, and, in some cases, completely eradicated the | Immunology ...

At the beginning of the COVID-19 pandemic, numerous studies had shown that COVID-19 patients with high levels of ...

A MedUni Vienna study has identified a new approach to the drug treatment of metabolic liver diseases. In an experimental ...

A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at . The webcast will be archived and available for replay for 30 days after the event.

Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer’s.

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 ...

Technical analysis for Intra-cellular Therapies Inc. ITCI including support levels resistance levels and stop losses for ITCI ...